Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 423 recruiting now early-phase tilt #1 of 28,963 conditions

Breast Cancer: early-phase trial registry

423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1 of 28,963 conditions by registered trial count.

1,251 US clinical trials · 423 currently recruiting · #1 of 28,963 conditions by registered trial count

Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.

Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.

Open enrollment, early-phase tilt

Breast Cancer has 1,251 registered US clinical trials, 423 of them open to new participants right now, about 34% of the total.

423
recruiting participants now
34%
of trials open to enrollment
120
in Phase 3-4 (later-stage)
98
top sponsor: Memorial Sloan Kettering Cancer Center

Corpus placement: #1 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Breast Cancer is recruiting below its size-band peers.

    423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Breast Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.

  3. Typical Breast Cancer enrolment sits around 90 participants.

    Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.

  4. Breast Cancer research is mostly interventional.

    1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1235Phase 2256Phase 3100Phase 420

Open and recent trials

1,251 total, page 24 of 26

COMPLETED NA 20 participants

Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain

Saint John's Cancer Institute

NCT02548637

COMPLETED NA 20 participants

Feasibility of Providing a Purpose Renewal Intervention for Cancer Survivors Via Virtual Groups

Mary Radomski

NCT04767464

COMPLETED Phase 1 20 participants

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

Dana-Farber Cancer Institute

NCT00003761

COMPLETED 20 participants

The Use of Molecular Breast Imaging in the Evaluation of Tumor Response to Neoadjuvant Therapy in Women With Breast Cancer

Mayo Clinic

NCT01023802

COMPLETED Phase 1 19 participants

Effect of Aprepitant on Cyclophosphamide Pharmacokinetics in Patients With Breast Cancer

UNC Lineberger Comprehensive Cancer Center

NCT00719173

COMPLETED Phase 1 19 participants

Bright Light on Fatigue in Women Being Treated for Breast Cancer

Washington University School of Medicine

NCT02658708

COMPLETED Phase 2 19 participants

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

Jennifer Lee Caswell-Jin

NCT05101564

COMPLETED Phase 1 19 participants

Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT01502592

COMPLETED Phase 2 18 participants

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery

Translational Oncology Research International

NCT00769470

COMPLETED NA 18 participants

Dietary Fat, Eicosanoids and Breast Cancer Risk

USDA Grand Forks Human Nutrition Research Center

NCT01824498

COMPLETED Phase 1 18 participants

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

Poniard Pharmaceuticals

NCT00465725

COMPLETED NA 18 participants

Developing a Psychosexual Educational Partners Program: PEPP A Feasibility Study

University of Michigan Rogel Cancer Center

NCT05070299

COMPLETED Phase 1 18 participants

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Pfizer

NCT04803305

COMPLETED NA 17 participants

Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)

University of Arizona

NCT03365895

COMPLETED Phase 2 17 participants

Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients

Memorial Sloan Kettering Cancer Center

NCT02730130

COMPLETED NA 17 participants

Emotions Immunology and Breast Cancer

Luz A. Venta, MD

NCT03609671

COMPLETED 17 participants

CRRS-4 Pivotal Somo•v™ ABUS ROC Reader Observer Study

U-Systems

NCT01424956

COMPLETED NA 16 participants

Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia

OHSU Knight Cancer Institute

NCT00627276

COMPLETED 16 participants

Effects of Aromatase Inhibitor Therapy on Muscle Function

Tarah J Ballinger, MD

NCT03581552

COMPLETED Phase 2 16 participants

Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes

Case Comprehensive Cancer Center

NCT00007904

COMPLETED NA 16 participants

Increasing Physical Activity Among Breast Cancer Survivors With Depression

University of Texas Southwestern Medical Center

NCT02781051

COMPLETED Phase 1 16 participants

Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors

Masonic Cancer Center, University of Minnesota

NCT00703638

COMPLETED 16 participants

Breast Computed Tomography (CT) as a Diagnostic Tool

Emory University

NCT00957307

COMPLETED NA 15 participants

Purpose Project: Reclaiming Life Purpose After Breast Cancer (Feasibility Study)

Allina Health System

NCT03233334

COMPLETED Phase 1 15 participants

Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential

Genentech

NCT02621957

COMPLETED Phase 2 15 participants

Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Case Comprehensive Cancer Center

NCT00253500

COMPLETED Phase 1 14 participants

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

NCT00574366

COMPLETED 14 participants

Collection of Blood Specimens for Circulating Tumor Cell Analysis

Viatar

NCT01943500

COMPLETED Phase 1 14 participants

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Syndax Pharmaceuticals

NCT01594398

COMPLETED NA 14 participants

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning

Milton S. Hershey Medical Center

NCT06028152

COMPLETED 14 participants

Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer

Massachusetts General Hospital

NCT00087347

COMPLETED NA 14 participants

Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

Case Comprehensive Cancer Center

NCT03650803

COMPLETED Phase 2 13 participants

Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

Masonic Cancer Center, University of Minnesota

NCT01105650

COMPLETED NA 13 participants

A Home-Based Study to Enhance Activity in Breast Cancer Survivors

Baystate Medical Center

NCT02969291

COMPLETED Phase 1 13 participants

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

Duke University

NCT00674791

COMPLETED NA 13 participants

Imaging the Patterns of Breast Cancer Early Metastases

University of Florida

NCT02706964

COMPLETED Phase 1 12 participants

Irinotecan and Capecitabine in Treating Women With Advanced Breast Cancer

Roswell Park Cancer Institute

NCT00083148

COMPLETED NA 12 participants

Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions

Mayo Clinic

NCT01806558

COMPLETED Early Phase 1 12 participants

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

Creighton University

NCT01697345

COMPLETED Phase 1 11 participants

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

National Cancer Institute (NCI)

NCT03384316

COMPLETED NA 11 participants

Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer

Memorial Sloan Kettering Cancer Center

NCT02521363

COMPLETED Phase 4 10 participants

A Study of Serum Folate Levels in Patients Treated With Olaparib

Rush University Medical Center

NCT04024254

COMPLETED Phase 2 10 participants

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

H. Lee Moffitt Cancer Center and Research Institute

NCT02402764

COMPLETED NA 10 participants

Acupuncture for Anxiety in Women With Breast Cancer: A Feasibility Study

University of New Mexi

NCT00322504

COMPLETED NA 10 participants

Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring

UConn Health

NCT02092636

COMPLETED 10 participants

Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts

Dartmouth-Hitchcock Medical Center

NCT02752893

COMPLETED Early Phase 1 10 participants

ICG and SLN Mapping

University of Wisconsin, Madison

NCT05859971

COMPLETED Phase 2 10 participants

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Columbia University

NCT01847001

COMPLETED Phase 2 10 participants

Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients With Metastatic Breast Cancer

Kari Kendra

NCT00201760

COMPLETED Phase 2 9 participants

Trastuzumab and Irinotecan in Treating Patients With HER2/Neu Positive Metastatic Breast Cancer

University of California, San Francisco

NCT00303992

← Previous Page 24 of 26 Next →

Phase Distribution

PhaseTrial count
Phase 1 235
Phase 2 256
Phase 3 100
Phase 4 20

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Breast Cancer right now

423 recruiting of 1,251 indexed (34% open).

Phase mix: 120 late (III/IV) vs 491 early (I/II) (early-phase heavy).

Top sponsor: Memorial Sloan Kettering Cancer Center (98 trials), 9 others listed. 50 shown below, recruiting first. #1 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Breast Cancer?

PlainTrial tracks 1,251 US clinical trials for Breast Cancer, of which 423 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Breast Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.